NeurAxon

About:

NeurAxon discovers and develops pain therapeutics targeted on neuronal nitric oxide synthase.

Top Investors: H.I.G. Capital, OrbiMed, BDC Venture Capital, CTI Life Sciences Fund, Delphi Ventures

Description:

NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.

Total Funding Amount:

$57.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Toronto, Ontario, Canada

Founded Date:

2004-01-01

Founders:

John Andrews

Number of Employees:

11-50

Last Funding Date:

2012-05-01

IPO Status:

Private

Industries: